Coastal Carolina Research Center - Alcanza - HyperCore — North Charleston, South Carolina

Coastal Carolina Research Center - Alcanza - HyperCore is a clinical research site located in North Charleston, South Carolina, United States 29405.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Coastal Carolina Research Center - Alcanza - HyperCore has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Pneumococcal Vaccines.

Sponsors: Vaxcyte, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in North Charleston

Browse all research sites in South Carolina · View every site in North Charleston

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Coastal Carolina Research Center - Alcanza - HyperCore?

Coastal Carolina Research Center - Alcanza - HyperCore has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Coastal Carolina Research Center - Alcanza - HyperCore conducted?

Coastal Carolina Research Center - Alcanza - HyperCore has 1 clinical trials on record, with 1 currently active. Their work covers Pneumococcal Vaccines.

Is Coastal Carolina Research Center - Alcanza - HyperCore accredited by Crixeo Clinical Trials?

Coastal Carolina Research Center - Alcanza - HyperCore has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Coastal Carolina Research Center - Alcanza - HyperCore?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.